ChordNews
← All news

Starling Oncology expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M

By ChordNews · First written

Comments 0

Summary

Starling Oncology expects 2026 revenue of $650 million to $660 million and adjusted EBITDA of $4 million to $6 million, according to a Seeking Alpha breaking news headline. The company is also targeting 100% capitated revenue growth in 2027. This summary is based on the headline alone; no further details were available in the provided material.

This continues an earlier story: Tactile Medical sets 2026 adjusted EBITDA target of $50M-$52M and keeps revenue outlook at $360M-$366M

Timeline

  1. Seeking Alpha

    Source ↗

    Seeking Alpha reports that Starling Oncology expects $650M-$660M in revenue and $4M-$6M in adjusted EBITDA in 2026, while targeting 100% capitated revenue growth in 2027.

Comments

No comments yet.

    to like and comment.

    © 2026 ChordNews